SecBot SecBot
PRESS-RELEASE ·Filed Apr 21, 2026

TLX

Telix Pharmaceuticals Limited
BULLISH
Impact 7/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Traders should monitor the ASCO presentation on June 1, 2026, for safety and dosimetry signals that could de-risk the broader ProstACT Global trial and boost confidence in TLX591-Tx’s differentiation. Positive data could catalyze re-rating ahead of Part 2 readout.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$10.33
T+0 close · Apr 21, 2026 · via day close
Latest settled
+1.26%
T+60 · $10.46
Vs SPY
−3.52%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 22 $10.33entry
  2. T+1 · 7mo ago −1.36%α −0.96% · $10.19
  3. T+5 · 7mo ago +1.06%α +1.01% · $10.44
  4. T+20 · 6mo ago −1.55%α −4.71% · $10.17
  5. T+60 · 4mo ago +1.26%α −3.52% · $10.46
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Telix Pharmaceuticals announced that safety and dosimetry data from Part 1 of its Phase 3 ProstACT Global trial for TLX591-Tx will be presented as a late-breaking oral presentation at the 2026 ASCO Annual Meeting. The selection for a high-profile session underscores the potential clinical relevance of its radiopharmaceutical therapy in metastatic castration-resistant prostate cancer.

Key Facts

  • Safety and dosimetry data from Part 1 of the ProstACT Global Phase 3 trial will be presented at ASCO 2026 as a late-breaking oral presentation.
  • Part 1 included 36 patients and assessed tolerability, biodistribution, and radiation dose profile of TLX591-Tx in combination with standard of care.
  • TLX591-Tx shows reduced kidney toxicity and minimal salivary/lacrimal gland uptake compared to other PSMA-targeted therapies.
  • The abstract was selected for a high-visibility session at ASCO, indicating strong interest from the oncology community.

Financial Impact

Potential long-term commercial upside due to favorable safety profile and high-visibility data readout, though no immediate revenue impact.

pipeline valueinvestor sentimentclinical progress

Risk Factors

  • TLX591-Tx remains investigational and has not received marketing authorization.
  • Part 1 data are preliminary and from a small cohort; efficacy results from the larger Part 2 are still pending.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3278510

Track record

27 reports on TLX

Performance horizon

10 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.

Filters
  1. Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
  2. Oct 20, 202627d ago 6-K Neutral 4/10 No price data
  3. Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
  4. Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
  5. Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  6. Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
  7. Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
  8. Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
  9. Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
  10. Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
Showing 10 of 27

US Market Status

Market Closed · Opens Wed (9h 45m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 21, 2026